Enterprise Value

-15.11M

Cash

22.46M

Avg Qtr Burn

-18.8M

Short % of Float

2.15%

Insider Ownership

21.92%

Institutional Own.

44.51%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AMT-101 (IL-10 oral agonist) Details
Pouchitis, Rheumatoid arthritis, Ulcerative colitis

Phase 3

Initiation

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

AMT-126 (IL-22) Details
GI barrier repair

Failed

Discontinued